We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sareum to Collaborate with Johnson & Johnson Pharmaceutical Research & Development
News

Sareum to Collaborate with Johnson & Johnson Pharmaceutical Research & Development

Sareum to Collaborate with Johnson & Johnson Pharmaceutical Research & Development
News

Sareum to Collaborate with Johnson & Johnson Pharmaceutical Research & Development

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sareum to Collaborate with Johnson & Johnson Pharmaceutical Research & Development"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sareum Holdings plc. has announced that it has entered into an initial 12-month collaborative agreement with Johnson & Johnson Pharmaceutical Research and Development (J&JPRD), a Division of Janssen Pharmaceutica N.V.

Under the terms of the agreement, Sareum will apply its skills in high throughput protein structure determination to assist J&JPRD scientists in developing new and improved therapeutics to help patients suffering from diseases of the central nervous system.

In return, Sareum will receive technology access fees and success dependent milestone payments.

Commenting on the agreement, Sareum’s Chief Executive Officer, Dr Tim Mitchell, said: “We are very excited to collaborate with J&JPRD and look forward to using our technology and expertise in this area to find new therapies for patients.”

Financial terms of the agreement were not disclosed.

Advertisement